Bayer Wins Approval for Asundexian, a First-in-Class Stroke-Prevention Drug
BAYRY has more than doubled off its 52-week low of $7.49.
Summary
Bayer secured approval for asundexian, a Factor XIa inhibitor aimed at cutting stroke risk. This is a genuine pipeline win for a company whose pharma story has been dominated by litigation overhang, and it lands with the stock trading near its 52-week high of $15.97, so the market has already been warming to the name. Asundexian is the key late-stage asset Bayer has been counting on to offset patent cliffs in its older drugs, so a regulatory green light is the outcome that matters most for the pharma segment. The OTC ADR BAYRY is the primary listing here; BAYZF is the same underlying German shares.
At the time of this announcement, BAYRY was trading at $15.91 on OTC in the Life Sciences sector, with a market capitalization of approximately $60.8B. The 52-week trading range was $7.49 to $15.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.